Contact Us
Drug Search Results
More Filters [+]

Eritoran

Alternative Names: eritoran, e5564, e-5564
Latest Update: 2024-07-12
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TLR4 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eritoran

Countries in Clinic: Australia, Belgium, Canada, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: COVID-19|Influenza, Human|Pneumonia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
REMAP-CAP

P3

Recruiting

Pneumonia|COVID-19|Influenza, Human

2026-02-01

Recent News Events

Date

Type

Title

02/01/2024

PubMed

 Glomus Tumors: A Systematic Review of the Sub-Saharan Africa Experience.

05/01/2023

PubMed

 The TLR4/NF-κB signaling pathway-mediated type 2 skewing of T helper cell in cough variant asthma was counteracted by ethanol extract of Anacyclus pyrethrum root.

03/01/2023

PubMed

 Simultaneous determination and quality evaluation of 16 compounds in Ligustri Lucidi Fructus covering different regions and processed products using ultra-high-performance liquid chromatography-mass spectrometry.

05/19/2022

News Article

 Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

10/26/2020

News Article

 Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial

06/30/2020

News Article

 REMAP-CAP to Partner With Eisai on Innovative Trial to Combat COVID

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions